The effect of mismatching and sharing of HLA-A, -B, and -DR antigens on kidney graft survival in Eurotransplant 1982 to 1988.
1. Cyclosporine significantly improved kidney graft survival by 10-15%. 2. Matching for HLA-DR, HLA-B + DR and HLA-A + B + DR improved kidney graft survival significantly in non-CsA-treated patients. 3. Matching for the HLA-A, -B, and -DR loci, apart and in combination, significantly improved kidney graft survival in CsA-treated patients. 4. The best kidney graft survival was observed in HLA-A + B + DR identical combinations treated with CsA (76% at 5 yrs).
Persijn
G G
GG
Eurotransplant Foundation, University of Leiden, The Netherlands.
D'Amaro
J
J
De Lange
P
P
Schreuder
G M
GM
Thorogood
J
J
Zantvoort
F
F
Van Rood
J J
JJ
D003524:Cyclosporins / Q000627:therapeutic use; D005060:Europe / Q000453:epidemiology; D006085:Graft Survival; D006680:HLA Antigens / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000706:statistics & numerical data; D015993:Life Tables; D010043:Outcome and Process Assessment, Health Care; D016019:Survival Analysis; D015996:Survival Rate
D003524:Cyclosporins; D006680:HLA Antigens